Unreliable Extended-Spectrum β-Lactamase Detection in the Presence of Plasmid-Mediated AmpC in Escherichia coli Clinical Isolates
- 1 February 2009
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 47 (2), 358-361
- https://doi.org/10.1128/jcm.01687-08
Abstract
The emergence of extended-spectrum β-lactamase (ESBL) and plasmid-mediated AmpC (pAmpC) enzymes in Escherichia coli raises concern regarding accurate laboratory detection and interpretation of susceptibility testing results. Twenty-six cefpodoxime ESBL screen-positive, cefoxitin-resistant E. coli clinical isolates were subjected to clavulanate ESBL confirmatory testing employing disk augmentation, Etest, and the BD Phoenix NMC/ID-132 panel. Phenotypic pAmpC production was assessed by boronic acid disk augmentation. ESBL and pAmpC genes were detected by gene amplification and sequencing. ESBL genes (SHV and/or CTX-M-type genes) were detected in only 7/26 ESBL screen-positive isolates. Of 23 aminophenylboronic acid screen-positive isolates, pAmpC genes were detected in 20 (CMY-2 or FOX-5 genes). High incidences of false-positive ESBL confirmatory results were observed for both clavulanate disk augmentation (9/19) and BD Phoenix (5/19). All were associated with the presence of pAmpC genes with or without TEM-1. Etest performed poorly, as the majority of interpretations were nondeterminable. In addition, false-negative ESBL confirmatory results were observed in isolates possessing concomitant ESBL and pAmpC genes for Etest (four of five), BD Phoenix (three of five), and disk augmentation (one of five). The results indicate poor performance of currently employed ESBL confirmatory methods in the setting of concomitant pAmpC. Some isolates with pAmpC and ESBL genes fell within the susceptible category to extended-spectrum cephalosporins, raising concern over currently employed breakpoints.This publication has 16 references indexed in Scilit:
- Prevalence and Significance of a Negative Extended-Spectrum β-Lactamase (ESBL) Confirmation Test Result after a Positive ESBL Screening Test Result for Isolates of Escherichia coli and Klebsiella pneumoniae : Results from the SENTRY Asia-Pacific Surveillance ProgramJournal of Clinical Microbiology, 2007
- Population-based Laboratory Surveillance for AmpC β-Lactamase–producing Escherichia coli, CalgaryEmerging Infectious Diseases, 2007
- Occurrence of plasmidic AmpC type β-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004)International Journal of Antimicrobial Agents, 2006
- Practical Methods Using Boronic Acid Compounds for Identification of Class C β-Lactamase-ProducingKlebsiella pneumoniaeandEscherichia coliJournal of Clinical Microbiology, 2005
- Occurrence of extended-spectrum β-lactamases among chromosomal AmpC-producing Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens in Korea and investigation of screening criteriaDiagnostic Microbiology and Infectious Disease, 2005
- Detection of Plasmid-Mediated AmpC β-Lactamase Genes in Clinical Isolates by Using Multiplex PCRJournal of Clinical Microbiology, 2002
- Diversity of CTX-M β-lactamases and their promoter regions fromEnterobacteriaceaeisolated in three Parisian hospitalsFEMS Microbiology Letters, 2002
- Molecular Correlation for the Treatment Outcomes in Bloodstream Infections Caused byEscherichia coliandKlebsiella pneumoniaewith Reduced Susceptibility to CeftazidimeClinical Infectious Diseases, 2002
- Plasmid-Determined AmpC-Type β-LactamasesAntimicrobial Agents and Chemotherapy, 2002
- Identification of CTX-M-14 Extended-Spectrum β-Lactamase in Clinical Isolates of Shigella sonnei , Escherichia coli , and Klebsiella pneumoniae in KoreaJournal of Clinical Microbiology, 2001